Q1 Earnings Estimate for Certara Issued By Leerink Partnrs

Certara, Inc. (NASDAQ:CERT) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Certara in a research report issued on Wednesday, February 26th. Leerink Partnrs analyst M. Cherny forecasts that the company will earn $0.05 per share for the quarter. The consensus estimate for Certara’s current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara’s Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.07 EPS and FY2026 earnings at $0.33 EPS.

Other research analysts also recently issued reports about the stock. Robert W. Baird cut their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Stephens restated an “overweight” rating and issued a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Barclays raised their price target on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday. Finally, TD Cowen initiated coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Certara presently has an average rating of “Moderate Buy” and an average target price of $15.83.

Certara Price Performance

CERT stock opened at $11.94 on Monday. The firm has a 50 day moving average of $12.48 and a 200-day moving average of $11.63. The firm has a market capitalization of $1.92 billion, a P/E ratio of -59.70, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. Certara has a 12 month low of $9.41 and a 12 month high of $19.87. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Hedge Funds Weigh In On Certara

Hedge funds and other institutional investors have recently modified their holdings of the company. ArrowMark Colorado Holdings LLC boosted its stake in Certara by 164.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after buying an additional 3,861,674 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Certara by 864.0% during the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock valued at $40,253,000 after purchasing an additional 3,387,590 shares during the last quarter. Brown Brothers Harriman & Co. purchased a new position in Certara in the 3rd quarter worth $27,292,000. Mackenzie Financial Corp purchased a new stake in Certara during the fourth quarter valued at about $17,852,000. Finally, Wasatch Advisors LP grew its stake in shares of Certara by 22.4% during the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after buying an additional 1,651,076 shares during the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.